Guardant Health (NASDAQ:GH) Raised to “Strong-Buy” at Mizuho

Guardant Health (NASDAQ:GH) was upgraded by stock analysts at Mizuho to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

GH has been the subject of several other reports. Stephens reiterated an “overweight” rating and issued a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. Piper Sandler upped their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Barclays cut their target price on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Thursday. Canaccord Genuity Group upped their price target on shares of Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Finally, Morgan Stanley increased their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. Twenty investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $49.00.

Guardant Health Price Performance

Shares of NASDAQ:GH traded up $0.59 on Wednesday, hitting $41.73. 123,834 shares of the company’s stock were exchanged, compared to its average volume of 2,127,475. The business’s 50 day simple moving average is $43.64 and its two-hundred day simple moving average is $35.54. The stock has a market capitalization of $5.15 billion, a price-to-earnings ratio of -11.67 and a beta of 1.45. Guardant Health has a 12 month low of $15.81 and a 12 month high of $50.89.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $201.81 million for the quarter, compared to analysts’ expectations of $192.50 million. Equities analysts forecast that Guardant Health will post -2.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Guardant Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Guardant Health by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after purchasing an additional 350,606 shares in the last quarter. Deep Track Capital LP grew its holdings in shares of Guardant Health by 7.0% during the fourth quarter. Deep Track Capital LP now owns 6,419,566 shares of the company’s stock valued at $196,118,000 after buying an additional 419,006 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after acquiring an additional 29,686 shares during the period. Two Sigma Advisers LP raised its stake in Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock worth $70,742,000 after acquiring an additional 1,138,300 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in Guardant Health by 38.5% in the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company’s stock worth $57,761,000 after acquiring an additional 525,368 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.